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ABSTRACT
N-methyl-D-aspartate (NMDA) receptor blockade in rodents induces behavioural and 
neurochemical changes reminiscent of schizophrenia symptoms and pathology. To 
examine how NMDA receptor blockade affects glutamatergic and GABAergic 
pathways when administered during early brain development, [3H]MK-801 and 
[3H]muscimol binding to NMDA and GABAA receptors was examined at four time-
points following injections of phencyclidine  (PCP) or saline on postnatal days (PN)7, 
9 and 11. [3H]MK-801 binding was significantly increased in PCP-treated rats in the 
thalamus from PN18 to PN96, in the prefrontal and anterior cingulate cortices at 
PN32, and in the hippocampus at PN96. In a similar manner, GABAA receptor 
binding was increased in PCP-treated rats in the thalamus and hippocampus from 
PN18 to PN96, and in the prefrontal and anterior cingulate cortices at PN32. 
Glutamatergic and GABAergic transmission is therefore chronically altered by this 
treatment, which has relevance to disease processes that may be involved in 
schizophrenia. 
Key words: brain development, GABAA receptor, NMDA receptor, phencyclidine, 
schizophrenia
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1. INTRODUCTION
Glutamate, predominantly through its actions on N-methyl-D-aspartate (NMDA) 
receptors, plays a key role in brain developmental processes such as neuronal 
migration, synaptogenesis and synaptic plasticity (McDonald and Johnston 1990; 
Pearce et al. 1987). The timing of expression of glutamate receptors appears to be 
crucial for normal brain development, since changes in the activity of glutamate 
receptors may interfere with these processes (Ritter et al. 2001; Ritter et al. 2002). 
During development in the rat, particularly postnatal days (PN)7–14, the brain is 
highly sensitive to the toxic effects of modulation of the NMDA receptor (Haberny et 
al. 2002), which may relate to the increased expression of specific NMDA receptor 
subunits (Mitani et al. 1998). Given the important role of the NMDA receptor in brain 
developmental processes, antagonism of this receptor could have severe long-term 
detrimental effects such as reduced and/or non-functional neuronal connections 
(Behar et al. 1999).
In rodents, treatment with NMDA receptor antagonists such as phencyclidine (PCP) 
and MK-801 during the perinatal period induces neuronal apoptosis (Fredriksson et al. 
2004; Hansen et al. 2004; Harris et al. 2003; Ikonomidou et al. 1999; Wang et al. 
2001). In the long-term, perinatal NMDA receptor blockade impairs cognitive 
function (Andersen and Pouzet 2004; Sircar 2003; Stefani and Moghaddam 2005; 
Wang et al. 2001; Wiley et al. 2003), sensorimotor gating (Harris et al. 2003; Wang et 
al. 2001; Wang et al. 2003) and locomotor activity (du Bois et al. 2008b; Facchinetti 
et al. 1993; Wang et al. 2001), which are particularly relevant to schizophrenia 
symptoms and pathology. Abnormal expression of neurotransmitter receptors 
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including dopamine D2 (du Bois et al. 2008a; Sircar and Soliman 2003) and NMDA 
(Harris et al. 2003; Wang et al. 2001; Wilson et al. 1998) is a further long-term 
consequence of perinatal NMDA receptor blockade. Recently it was shown that 
perinatal PCP treatment caused a selective loss of parvalbumin-containing 
(GABAergic) neurons in the cortex of rats at adulthood (Wang et al. 2007).
Hypofunction of NMDA receptors has been implicated in schizophrenia, since 
NMDA receptor anatgonists such as PCP and ketamine mimic schizophrenia 
symptoms so well in healthy individuals and strongly exacerbate symptoms in 
schizophrenia patients (Javitt and Zukin 1991). However, post mortem studies of the 
binding site of the NMDA receptor have revealed inconsistent results. Increased 
[3H]MK-801 binding has been reported in the anterior and posterior cingulate cortices 
(Newell et al. 2005; Zavitsanou et al. 2002), superior temporal gyrus (Nudmamud and 
Reynolds 2001) and putamen (Kornhuber et al. 1989) of schizophrenia patients versus 
controls, while binding was reported as unchanged in other areas including the frontal 
and entorhinal cortices, hippocampus and amygdala (Kornhuber et al. 1989). 
Conversely, decreased NMDA receptor binding has been observed in the 
hippocampus (Dean et al. 1999), using [3H]TCP. 
Findings also point to a deficit in GABAergic transmission in schizophrenia. 
Decreased GAD67, a marker for GABAergic terminals, has been found in the 
prefrontal cortex (Akbarian et al. 1995; Guidotti et al. 2000; Volk et al. 2000). 
Reductions of GABAergic interneurons have been found in anterior cingulate and 
prefrontal cortices and hippocampus (Benes et al. 1998; Benes et al. 1991). Moreover, 
reductions of parvalbumin-containing interneurons have been reported in superficial 
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layers of the prefrontal cortex (Beasley and Reynolds 1997; Reynolds et al. 2002). 
Deficits in GABA synthesis and release may therefore contribute to the observed 
increase in [3H]muscimol binding in several brain regions (Benes et al. 1992; Benes et 
al. 1996; Deng and Huang 2006; Newell et al. 2007). 
Along with perinatal PCP treatment of rodents, another developmental model of 
schizophrenia (prenatal methylazoxymethanol acetate (MAM) administration) has 
shown decreased parvalbumin-containing interneurons (Lodge et al. 2008), suggesting 
that common targets and pathways contribute to the schizophrenia-like pathology in 
these animal models. The fact that these models alter the expression of parvalbumin-
containing (GABAergic) neurons has important construct validity, as disinhibition of 
pyramidal neurons from reduced GABAergic activity is thought to contribute to 
schizophrenia pathology (Lisman et al. 2008). To further investigate alterations to key 
pathways implicated in schizophrenia, we investigated NMDA and GABAA receptor 
binding in various brain regions of rats at several time-points following perinatal PCP 
exposure, to determine if interruption to NMDA receptor function early in 
development can have persistent long-term consequences on brain function. We 
hypothesised that changes in NMDA receptor expression would tightly influence 
expression of GABAA receptors in brain regions examined. 
2. EXPERIMENTAL PROCEDURES
2.1 Animals
Timed pregnant Sprague-Dawley rats were obtained at gestation day 14 from the 
Animal Resource Centre (Perth, WA, Australia). They were housed individually 
under a 12:12-hour light-dark cycle in a temperature controlled environment. Food 
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and water was freely available. Day of birth was considered postnatal day (PN)0. 
Pups were sexed on PN7 and litters were assigned to PCP or saline groups (5 
litters/group). Male pups were kept in the litters until weaning but were not treated. 
Pups were weaned at PN24-28 and were then housed in pairs. Female rats were used 
because the literature shows that treating female rat pups on PN7, 9 and 11 with PCP 
produces apoptosis and alterations in sensorimotor gating, motor activity and working 
memory (Wang et al. 2001; Wiley et al. 2003), all of which have particular relevance 
to schizophrenia symptoms and pathology. This study was approved by the Animal 
Ethics Committee of the University of Wollongong, and procedures complied with the 
Australian Code of Practice for the Care and Use of Animal for Scientific Purposes, 
which conforms to International Guiding Principles for Biomedical Research 
Involving Animals. All efforts were made to minimize numbers of animals used and 
their suffering.
2.2 Perinatal PCP treatment
On PN7, 9 and 11, pups were given a subcutaneous injection of 10 mg/kg 
phencyclidine hydrochloride (Sigma, Castle Hill, NSW, Australia) or 0.9% NaCl at a 
volume of 1 ml/kg. Six rats from each group (PCP and control) were sacrificed at four 
different time-points (24 hr, 1 week, 3 weeks or 12 weeks) following their last 
injection for biochemical analyses, representing juvenile (PN12 and 18), adolescent 
(PN32) and adult (PN96) ages.
2.3 Histology
Rats were sacrificed by carbon dioxide asphyxiation and brains were removed and 
frozen in liquid nitrogen immediately after extraction. Brain tissue was kept at -80°C 
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until sectioning. Brains were cut into 14 µm coronal sections with a cryostat at -18oC, 
and were mounted on PolysineTM microscope slides. Sections were collected at levels 
approximately corresponding to bregma 3.70 and -5.20 mm, with the aid of a standard 
rat brain atlas (Paxinos and Watson 1986). Tissue sections were stored at -20oC until 
further use.
2.4 NMDA receptor binding
The method for NMDA receptor binding was taken from Newell et al. (2005). 
Sections were incubated at room temperature for 2.5 hr in 30 mM N-2-hydroxyethyl 
piperazine-N'-2-ethanesulphonic acid (HEPES) buffer, pH 7.5, containing 100 mM 
glycine, 100 mM glutamate, 1 mM ethylenediaminetetraacetic acid (EDTA) and 20 
nM [3H]MK-801 (specific activity 17.1 Ci/mmol, Perkin Elmer, Boston, 
Massachusetts, USA). Nonspecific binding was determined by incubating adjacent 
sections with [3H]MK-801 in the presence of 20 mM MK-801. Following incubation, 
sections were washed twice for 20 min each at 0ºC in 30 mM HEPES containing 1 
mM EDTA (pH 7.5). Autoradiographic images for NMDA receptor binding were 
taken using a Beta-ImagerTM camera (BioSpace, Paris, France). Sections were 
scanned for 3.5 hr at a high-resolution setting. A series of sections with known 
amount of radioactivity were used as standards in all scans. Quantitative analysis of 
these images was performed using the program β-Image Plus (version 4, BioSpace).
2.5 GABAA receptor binding
The method for GABAA receptor binding followed that of Newell et al. (2007). 
Sections were pre-incubated three times for 5 min at 4ºC in 50 mM Tris-citrate (pH 
7). Sections were then incubated for 45 min at 4ºC in the same buffer containing 3 nM 
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[3H]muscimol (specific activity 29.5 Ci/mmol; PerkinElmer, USA). Non-specific 
binding was determined by the addition of 100 µM GABA to adjacent sections. 
Following incubation, sections were rinsed four times for 2 s in 4ºC buffer and dried 
in a stream of cool air. Sections were opposed to Kodak BioMax MR film with 
Amersham microscales for 12 weeks. Autoradiographs were developed using Kodak 
GBX developer and fixed with Kodak GBX fixer. Autoradiographic images were 
captured and analysed using a computer-assisted image analysis system, Multi-
Analyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, California).
2.6 Quantification
A set of sections from each age and treatment group were stained with cresyl violet 
for confirmation of anatomical structures. Specific binding was calculated by 
subtracting non-specific binding from total binding. Non-specific binding was less 
than 30% of total binding. The data presented is the average of three brain sections 
from each of the six rats per group. Areas quantified included the prefrontal and 
anterior cingulate cortices, the ventral thalamus and hippocampus. Sub-regions of the 
hippocampus (CA1-3) were quantified, but no differences were found so the mean of 
the sub-regions was used in the results.
2.7 Statistical Analyses
Statistical analyses were performed using SPSS (version 15.0, SPSS Inc., Chicago). 
Two-way (age x treatment) ANOVAs were used to analyse NMDA and GABAA
receptor binding among individual brain regions. Unpaired two-tailed t-tests were 
used to compare binding across developmental time-points and for comparing binding 
in PCP and control groups at individual time-points. Pearson’s correlations were used 
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to examine the relationship between NMDA and GABAA receptor binding at 
individual time-points in overall groups. Data is expressed as means ± S.E. 
Significance was set at p<0.05. The measurement of radioligand binding signals is 
presented in fmoles/mg of tissue equivalent. 
3. RESULTS
3.1 NMDA receptor binding across developmental time-points
Prefrontal cortex
In the prefrontal cortex, there were significant main effects of age (F3, 34 = 107.35, 
p<0.001) and treatment (F1, 34 = 23.20, p<0.001), as well as interaction between the 
two factors (F3, 34 = 4.23, p<0.01).  NMDA receptor binding significantly increased 
with age in the control group from PN12 to PN96 (p<0.01). In the PCP group binding 
also progressively increased but this was only significant from PN12 to PN18 
(p<0.001). In terms of treatment effects, NMDA receptor binding was significantly 
increased in PCP-treated rats at PN18 (18%, p<0.001) and 32 (16%, p<0.05) 
compared to controls (Fig. 1A). At PN96 there was no change compared to controls.
Anterior cingulate cortex 
The anterior cingulate cortex also showed significant main effects of age (F3, 37 = 
191.29, p<0.001) and treatment (F1, 37 =25.21, p<0.001), as well as interaction 
between the two factors (F3, 37 = 28.81, p<0.001). In terms of age differences, NMDA 
receptor binding progressively increased significantly until PN96 in the control group 
(p<0.05). Conversely, in the PCP group, binding significantly increased until PN32 
(p<0.001) and then declined at PN96 (p<0.01). Perinatal PCP treatment had the effect 
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of significantly increasing NMDA receptor binding (Fig. 1B) at PN32 only (37%, 
p<0.001; Fig. 2A, B) compared to controls.
Thalamus
In the thalamus there were significant main effects of age (F3, 40 = 263.7, p<0.001) 
and treatment (F1, 40 =95.0, p<0.001), as well as interaction between the two factors 
(F3, 40 = 12.7, p<0.001). The control group displayed a temporal pattern whereby 
binding increased from PN12 to PN18 (p<0.001) then increased slightly more from 
PN32 to PN96 (p<0.05). The PCP-treated group also showed a large increase in 
binding from PN12 to PN18 (p<0.001), but this was then followed by a further 
increase at PN32 (p<0.01) with no change at PN96. In terms of treatment effects, 
there were increases in NMDA receptor binding at PN18 (12%), PN32 (29%) and 
PN96 (22%) compared to the control group (p’s <0.001; Fig. 1C).
Hippocampus
In the hippocampus there was a main effect of age (F3,40 = 283.52, p<0.001) but not 
treatment (F1,40 = 0.186, p=0.669), although there was significant interaction between 
the two factors (F3,40 = 17.78, p<0.001). Control rats showed an increase in binding 
up until PN32 (p<0.01) and PCP rats showed progressive increases in binding until 
PN96, significant at all points (p<0.001) except from PN18 to PN32. Perinatal PCP 
treatment increased NMDA receptor binding by 14% at adulthood only, compared to 
controls (p<0.001; Fig 1D). 
3.2 GABAA receptor binding across developmental time-points
Prefrontal cortex
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In the PFC, there were significant main effects of age (F3,38 = 66.7; p<0.001) and 
treatment (F1,38 = 18.1; p<0.001) on GABAA receptor binding, as well as significant 
interaction between the two factors (F3,38 = 11.7; p<0.001). In terms of age effects, the 
control group generally showed increased binding until PN96 (p<0.05). In the PCP 
group, binding increased with age from PN18 to PN32 (p<0.05) then remained 
unchanged. In terms of treatment effects, PCP-treated rats showed increased  GABAA
receptor binding levels compared to controls at PN32 (43%; p<0.001), while there 
were no differences at the other time-points (Fig. 1E).
Anterior cingulate cortex
In the ACC, there was a significant main effect of age (F3,39 = 30.5; p<0.001) but not 
treatment, although there was a significant interaction between the two factors (F3,39 = 
15.0; p<0.001). When looking at the temporal pattern of GABAA receptor binding, 
control rats showed increased binding levels at PN18 (p<0.05), followed by a further 
increase at PN96 (p<0.01). In PCP-treated rats, GABAA receptor binding increased 
with age until PN32 (p<0.05), after which it significantly declined (p<0.001). Similar 
to the prefrontal cortex, GABAA receptor binding levels were significantly elevated 
(59%; p<0.001; Fig. 2C, D) in PCP-treated rats compared to controls at PN32, while 
there were no significant differences at other time-points (Fig. 1F). 
Thalamus
In the thalamus, there were significant main effects of age (F3,34 = 70.0; p<0.001) and 
treatment (F1,34 = 44.8; p<0.001) on GABAA receptor binding, as well as significant 
interaction between the two factors (F3,34 = 6.5; p<0.001). In terms of age effects, the 
control group showed no changes in the level of GABAA receptor binding until PN96 
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when levels significantly declined (p<0.001). Conversely, in PCP-treated rats, binding 
was significantly increased at PN18 and 32 compared PN12 (p<0.01), and binding 
was significantly lower at PN96 than all other ages (p<0.001). In terms of treatment 
effects, GABAA receptor binding was significantly elevated (27-47%; p<0.01) in 
PCP-treated rats compared to controls at all ages from PN18 onwards (Fig 1G).
Hippocampus 
In the hippocampus, there were significant main effects of age (F3,34 = 79.5; p<0.001) 
and treatment (F1,34 = 28.9; p<0.001) on GABAA receptor binding, as well as 
significant interaction between the two factors (F3,34 = 4.8; p<0.01). When looking at 
the temporal pattern of GABAA receptor binding, control rats showed a reduction in 
binding at PN32 (p<0.05) and PN96 (p<0.001) compared to earlier time-points. PCP-
treated rats showed a different pattern of binding, with an increase at PN18 (p<0.01), 
followed by reductions at PN32 and PN96 (p<0.001). Similar to what was observed in 
the thalamus, the PCP-treated group showed increased GABAA receptor binding 
compared to controls (22-45%; p<0.05) at all time-points from PN18 onwards (Fig 
1H). 
3.3 The relationship between NMDA and GABAA receptor binding in brain regions 
examined
GABAA receptor binding levels were highly correlated with NMDA receptor binding 
levels in the brain regions and time-points that both NMDA and GABAA receptor
binding were changed. There were significant positive correlations between NMDA 
and GABAA receptor binding at PN32 in the prefrontal (r=0.876, p<0.001) and 
anterior cingulate (r=0.934, p<0.001) cortices (Fig. 3A, B). In the thalamus, there was 
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a significant positive correlation between NMDA and GABAA receptor binding at 
PN18 (r=0.614, p<0.05), 32 (r=0.751, p<0.01) and 96 (r=0.829, p<0.01; Fig. 3C).
Finally, in the hippocampus, there was a significant positive correlation between 
NMDA and GABAA receptor binding at PN96 (r=0.919, p<0.001; Fig3D). 
4. DISCUSSION
The present study examined how NMDA and GABAA receptor binding are altered 
during the course of brain development following perinatal PCP treatment. We found 
that the pattern of change of these two systems was remarkably similar and highly 
correlated in all regions examined, highlighting the close relationship between the two 
systems. In PCP-treated rats, the thalamus and hippocampus both showed increased 
NMDA and GABAA receptor binding levels compared to controls, which were still 
evident at adulthood. The prefrontal and anterior cingulate cortices also showed 
increased binding of these two receptors, mainly at adolescence. Control rats 
displayed developmental patterns of [3H]MK-801 and [3H]muscimol binding that are 
consistent with previous reports from the literature (Facchinetti et al. 1993; Insel et al. 
1990; Morin et al. 1989; Xia and Haddad 1992). 
Perinatal administration of NMDA receptor antagonists is known to induce massive 
increases in neuronal apoptosis (Fredriksson et al. 2004; Hansen et al. 2004; Harris et 
al. 2003; Ikonomidou et al. 1999; Wang et al. 2001). In fact, using corticostriatal 
slices from PN7 rats, Wang et al. (2005) showed that PCP-induced apoptosis required 
upregualtion of NR1 and NR2A polypeptides. Co-incubation of PCP with an 
antisense oligodeoxynucleotide specific to the NR1 and NR2A mRNAs prevented 
both PCP-induced NR1 and NR2A upregulation and cortical DNA fragmentation. We 
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did not observe any NMDA receptor binding changes at PN12. It is possible that the 
concomitant effects of apoptosis and NMDA receptor upregulation balance out any 
overall change in binding 24hrs after treatment cessation. Alternatively, changes in 
receptor expression levels may require more time to become evident at the protein 
level.
Wang et al. (2001) reported increased expression of NR1 one day after cessation of 
perinatal PCP treatment in the basal forebrain and not the hippocampus. In addition, 
an acute study where rats were treated with MK-801 on PN7 showed that expression 
of the obligatory NMDA receptor subunit, NR1, was increased in the ventral part of 
the hippocampus in adulthood (Harris et al. 2003). These results are consistent with
our binding results that show NMDA receptor upregualtion in cortical regions shortly 
following treatment and upregualtion of binding in the hippocampus in adulthood. No 
studies on the effects of perinatal NMDA receptor blockade on [3H]muscimol binding 
are available in the literature for comparison. It is unclear why the prefrontal and 
anterior cingulate cortices only showed changes at adolescence while the thalamus 
and hippocampus were affected at all time-points from PN18 onwards. The varying 
response of different brain regions to PCP treatment may be due to innate differences 
in organisation and connectivity (Benes 2000), as well as differences in temporal 
expression of NMDA and GABAA receptors. The observation that certain regions are 
affected only at adolescence, and that this time-point shows the greatest magnitude of 
change suggests an increased vulnerability of the brain to further adverse impacts at 
this developmental stage.
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An explanation for the sustained increase in NMDA and GABAA receptor binding 
seen in PCP-treated rats is that perinatal NMDA receptor blockade could lead to a loss 
of or improper wiring of glutamatergic neurons and a decrease in glutamatergic 
transmission. This would be expected to cause a compensatory upregulation of 
NMDA receptors. Decreased glutamatergic activation of NMDA receptors, as well as 
AMPA and kainate receptors on GABAeric interneurons would be expected to reduce 
activity of those cells, thereby decreasing GABA release and causing compensatory 
increase in GABAA receptor levels. This could explain the strong positive correlation 
between NMDA and GABAA receptor binding observed in the present study. 
Investigation of AMPA and kainate receptor densities following perinatal PCP 
treatment would help to clarify the contribution of glutamate levels to PCP-induced 
pathology. 
Alternatively, blockade of NMDA receptors during the critical period of receptor 
sensitivity could by some unknown mechanism, cause an upregulation of NMDA 
receptors which never returns to normal. This blockade could also selectively destroy 
specific GABAergic neuronal populations, and therefore a decrease in the number of 
GABA-producing cells may lead to an upregulation of GABAA receptors. In support 
of this, Wang et al. (2007) found that perinatal PCP treatment resulted in the selective 
loss of parvalbumin-containing interneurons in cortical brain regions in early 
adulthood. However, the widespread upregulation of GABAA in the present study 
suggests that perhaps a combination of both deficits in glutamatergic transmission and 
loss of specific neuronal populations contribute to increased binding of both NMDA 
and GABAA receptors.   
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A loss of or decreased stimulation GABAegic cells would presumably lead to 
disinhibition and over-excitation of pyramidal neurons. In the prefrontal cortex, a 
reduction in GABAergic transmission would reduce inhibitory inputs to pyramidal 
neurons, resulting in less filtering of noise, which could contribute to cognitive 
deficits seen in this model (Andersen and Pouzet 2004; Wang et al. 2001; Wiley et al. 
2003). Similarly, in schizophrenia, disinhibition of pyramidal neurons through a loss 
of GABAergic outputs is thought to contribute to symptoms of the disorder (Lisman 
et al. 2008). In the hippocampus, disinhibition of pyramidal neurons could elevate 
activity of ventral tegmental area (VTA) neurons. This elevation of VTA activity has 
been shown to occur in another schizophrenia animal model which has deficits in 
hippocampal interneurons caused by prenatal methylazoxymethanol acetate (MAM) 
administration, and can be reversed by inactivating the subiculum (Lodge and Grace 
2007). This is consistent with our previous findings of elevated tyrosine hydroxylase 
mRNA expression in the VTA, and decreased D2 receptor binding in striatum 
following perinatal PCP treatment, which we suggest reflects increased dopamine 
output from the VTA (du Bois et al. 2008a).
Our finding that perinatal blockade of NMDA receptors may lead to long-term 
deficits in glutamatergic and GABAergic neurotransmission is relevant to 
schizophrenia pathology and treatment. Interestingly, co-administering agents that 
enhance GABAergic transmission with antipsychotic drugs provide more effective 
therapy to schizophrenia patients than antipsychotics alone (Casey et al. 2003; Wassef 
et al. 2000), including in treatment-resistant patients (Dursun and Deakin 2001; 
Tiihonen et al. 2003). Moreover, agents which enhance NMDA receptor channel 
activity such as agonists of the glycine binding site (eg. D-cycloserine, glycine and D-
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serine), and sarcosine, a glycine transport inhibitor, have had good success in treating 
when co-administered with antipsychotic drugs (Coyle and Tsai 2004; Lane et al. 
2006; Tsai et al. 2004). In addition, it has been recently shown that an mGlu2/3 
agonist is effective alone in treating symptoms (Patil et al. 2007), and part of the 
effect may be related to enhancement of postsynaptic NMDA receptor function 
(Tyszkiewicz et al. 2004). Recently, Andersen and Pouzet (2004) showed that 
cognitive impairments in the Morris water maze task resulting from perinatal PCP 
treatment of Sprague-Dawley rats could be reversed with chronic D-serine treatment, 
which further supports the idea of NMDA receptor hypofunction in this model and 
has good predictive validity for schizophrenia.
In summary, this study has shown that blockade of NMDA receptors persistently 
affects NMDA and GABAA receptor binding levels during the course of brain 
development. It would appear that the binding changes reflect deficits in excitatory 
and inhibitory neurotransmission, consistent with what has been reported by others in 
this model. This could result in the disinihibition of pyramidal neurons, which would 
have flow on effects such as causing a hyperdopaminergic state. Further studies 
examining these possibilities are required before any firm conclusions can be made. 
The perinatal NMDA receptor antagonist treatment model therefore represents some 
of the possible disease processes that may be involved in psychiatric disorders such as 
schizophrenia.
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Figure legends:
Figure 1. NMDA receptor binding (A-D) and GABAA receptor binding (E-H) in PCP-
treated and control rats across developmental time-points. Abbreviations: ACC, 
anterior cingulate cortex; GABAAR, GABAA receptor; Hipp, hippocampus; 
NMDAR, NMDA receptor; PCP, phencyclidine; PFC, prefrontal cortex; PN, 
postnatal day, Thal, thalamus. *p<0.05 vs. control at individual time-point.
Figure 2. NMDA receptor binding is shown in the anterior cingulate cortex of control 
(A) and PCP-treated (B) groups at PN32. Similarly, GABAA receptor binding is 
shown in the anterior cingulate cortex control (C) and PCP-treated (D) groups at 
PN32, where the greatest magnitude of change in NMDA and GABAA receptor 
binding was observed. Abbreviations: ACC, anterior cingulate cortex; PCP, 
phencyclidine; PN, postnatal day. 
Figure 3. Correlation between GABAA and NMDA receptor binding in the anterior 
cingulate and prefrontal cortices at PN32 (A and B) and in the thalamus and 
hippocampus at PN96 (C and D). Control rats are indicated by the square markers and 
PCP-treated rats by the diamond markers. Abbreviations: ACC, anterior cingulate 
cortex; Hipp, hippocampus; PFC, prefrontal cortex; PN, postnatal day; Thal, 
thalamus. 
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